Intellia Historical Financial Ratios
| NTLA Stock | USD 14.49 0.16 1.09% |
Intellia Therapeutics is lately reporting on over 104 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 385 will help investors to properly organize and evaluate Intellia Therapeutics financial condition quickly.
Intellia |
About Intellia Financial Ratios Analysis
Intellia TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Intellia Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Intellia financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Intellia Therapeutics history.
Intellia Therapeutics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Intellia Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Intellia Therapeutics sales, a figure that is much harder to manipulate than other Intellia Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Research And Ddevelopement To Revenue
The ratio of a company's research and development expenses to its total revenue, indicating how much of the revenue is invested back into developing new products or services.Tangible Asset Value
The total value of a company's physical, tangible assets, excluding intangible assets like patents and trademarks.Most ratios from Intellia Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Intellia Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Intellia Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.At present, Intellia Therapeutics' PTB Ratio is projected to increase slightly based on the last few years of reporting. The current year's Days Sales Outstanding is expected to grow to 385.16, whereas Price To Sales Ratio is forecasted to decline to 51.24.
| 2021 | 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 22.43 | 26.39 | 366.82 | 385.16 | PTB Ratio | 8.06 | 2.17 | 2.58 | 2.74 |
Intellia Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Intellia Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Intellia Therapeutics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 16.08 | 52.52 | 253.61 | 51.53 | 74.61 | 51.24 | |
| Ptb Ratio | 2.57 | 5.78 | 8.06 | 2.17 | 2.58 | 2.74 | |
| Days Sales Outstanding | 39.12 | 13.41 | 22.43 | 26.39 | 366.82 | 385.16 | |
| Book Value Per Share | 5.71 | 9.41 | 14.67 | 16.05 | 11.83 | 8.1 | |
| Free Cash Flow Yield | (0.11) | (0.12) | (0.16) | (0.0176) | (0.0284) | (0.15) | |
| Operating Cash Flow Per Share | (2.19) | (0.89) | (3.17) | (4.33) | (4.44) | (4.66) | |
| Stock Based Compensation To Revenue | 0.35 | 0.34 | 1.42 | 1.75 | 3.7 | 3.88 | |
| Capex To Depreciation | 1.22 | 0.57 | 1.85 | 7.71 | 1.56 | 1.48 | |
| Pb Ratio | 2.57 | 5.78 | 8.06 | 2.17 | 2.58 | 2.74 | |
| Ev To Sales | 15.18 | 50.44 | 252.11 | 43.99 | 71.54 | 45.98 | |
| Free Cash Flow Per Share | (2.33) | (0.96) | (3.35) | (5.09) | (4.6) | (4.83) | |
| Roic | (0.36) | (0.24) | (0.25) | (0.38) | (0.48) | (0.51) | |
| Net Income Per Share | (1.96) | (2.24) | (3.66) | (6.37) | (5.42) | (5.69) | |
| Days Of Inventory On Hand | 3.0E-6 | (46.46) | (17.9K) | (3.3K) | (3.8K) | (4.0K) | |
| Payables Turnover | 27.51 | 14.38 | 0.71 | 1.47 | 1.2 | 1.14 | |
| Sales General And Administrative To Revenue | 0.95 | 0.76 | 2.15 | 1.73 | 3.21 | 3.37 | |
| Capex To Revenue | 0.39 | 0.21 | 0.16 | 0.0618 | 1.12 | 0.31 | |
| Cash Per Share | 5.92 | 10.67 | 10.56 | 15.49 | 10.28 | 11.72 | |
| Pocfratio | (6.71) | (61.02) | (37.25) | (8.06) | (6.87) | (7.21) | |
| Capex To Operating Cash Flow | (0.0658) | (0.0718) | (0.0567) | (0.18) | (0.0355) | (0.0373) | |
| Pfcf Ratio | (6.3) | (56.93) | (35.25) | (6.86) | (6.63) | (6.96) | |
| Days Payables Outstanding | 13.27 | 25.38 | 511.3 | 248.44 | 303.03 | 318.18 | |
| Income Quality | 1.04 | 0.37 | 0.84 | 0.7 | 0.82 | 0.86 | |
| Roe | (0.34) | (0.24) | (0.25) | (0.4) | (0.46) | (0.48) | |
| Ev To Operating Cash Flow | (6.34) | (58.6) | (37.03) | (6.88) | (6.59) | (6.91) | |
| Pe Ratio | (7.48) | (24.26) | (32.28) | (5.48) | (5.62) | (5.91) | |
| Return On Tangible Assets | (0.28) | (0.19) | (0.2) | (0.32) | (0.37) | (0.39) | |
| Ev To Free Cash Flow | (5.95) | (54.68) | (35.04) | (5.85) | (6.36) | (6.68) | |
| Earnings Yield | (0.15) | (0.13) | (0.0412) | (0.031) | (0.18) | (0.19) | |
| Net Debt To E B I T D A | 0.39 | 0.93 | 0.19 | 0.87 | 0.22 | 0.21 | |
| Current Ratio | 8.12 | 9.3 | 6.11 | 9.61 | 8.67 | 6.55 | |
| Tangible Book Value Per Share | 5.71 | 9.41 | 14.67 | 16.05 | 11.83 | 8.1 | |
| Receivables Turnover | 9.33 | 27.23 | 16.27 | 13.83 | 1.0 | 0.95 | |
| Graham Number | 15.88 | 21.8 | 34.78 | 47.96 | 37.99 | 35.3 | |
| Shareholders Equity Per Share | 5.71 | 9.41 | 14.67 | 16.05 | 11.83 | 8.1 | |
| Graham Net Net | 4.63 | 7.86 | 4.62 | 11.38 | 7.76 | 8.31 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Intellia Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intellia Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intellia Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intellia Therapeutics Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Intellia Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intellia Therapeutics. If investors know Intellia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intellia Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.45) | Revenue Per Share 0.449 | Quarterly Revenue Growth (0.24) | Return On Assets (0.28) | Return On Equity (0.52) |
The market value of Intellia Therapeutics is measured differently than its book value, which is the value of Intellia that is recorded on the company's balance sheet. Investors also form their own opinion of Intellia Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Intellia Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intellia Therapeutics' market value can be influenced by many factors that don't directly affect Intellia Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intellia Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Intellia Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intellia Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.